Targeting DNA changes to treat Huntington's disease
Therapeutic targeting of DNA methyltransferases in Huntington's disease
This study is looking at how changing certain chemical tags on DNA might help slow down Huntington's disease by using mice to see how these changes affect the brain and behavior, with the hope of finding new ways to treat people with the condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11042817 on NIH RePORTER |
What this research studies
This research investigates how altering DNA methylation can affect gene expression and potentially slow down the progression of Huntington's disease (HD). By using mouse models, the study aims to understand how these changes impact brain function and behavior in HD. The researchers will administer a DNA demethylating agent and observe its effects on the disease's pathology and symptoms. This approach seeks to uncover new therapeutic targets that could lead to effective treatments for patients suffering from HD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Huntington's disease, particularly those in the early stages of the condition.
Not a fit: Patients with advanced Huntington's disease or those without a confirmed diagnosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow the progression of Huntington's disease and improve the quality of life for patients.
How similar studies have performed: While targeting DNA methylation is a relatively novel approach in Huntington's disease, similar strategies have shown promise in other neurodegenerative conditions, suggesting potential for success.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Yano, Hiroko — Washington University
- Study coordinator: Yano, Hiroko
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.